scholarly journals Effects of Hormone Replacement Therapy on Insulin Resistance in Postmenopausal Diabetic Women

2016 ◽  
Vol 4 (1) ◽  
pp. 83-88 ◽  
Author(s):  
Iskra Bitoska ◽  
Branka Krstevska ◽  
Tatjana Milenkovic ◽  
Slavica Subeska-Stratrova ◽  
Goran Petrovski ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
The Other ◽  
Control Group ◽  
Model Assessment ◽  
Improve Insulin Resistance ◽  
Homeostatic Model Assessment

BACKGROUND: Insulin resistance (IR) is closely associated with diabetes mellitus. On the other hand, increased visceral fat in menopause is also associated with IR, which makes postmenopausal diabetic women in a big risk for cardiovascular diseases. There are conflicting reports about the effects on hormone replacement therapy (HRT) on IR.AIM: The aim of the study was to investigate the effects of HRT on IR.METHODS: A total of 40 postmenopausal women with type 2 diabetes were enrolled and followed for 12 months. Half of them were assigned to take HRT, while the other half made the control group. Fasting plasma glucose (FPG) and insulinemia were measured in both groups at baseline and after 12 months. IR was represented by Homeostatic model assessment for IR (HOMA-IR).RESULTS: HRT was associated with significant decrease in HOMA-IR, FPG and insulinemia in the examined group. There was no significant reduction in FPG and no significant increase in insulinemia levels and HOMA-IR values in control group after 12 months.CONCLUSION: HRT was associated with statistically signifficant increase of insulin sensitivity. Larger clinical trials will be necessary to understand whether HRT may improve insulin resistance and glucose homeostasis in women with diabetes, especially when given shortly after entering menopause.

scholarly journals Association Between Hormone Replacement Therapy and Glycemic Control in Postmenopausal Women with Type 2 Diabetes

2015 ◽  
Vol 69 (1) ◽  
pp. 35-39
Author(s):  
Iskra Bitoska ◽  
Brankica Krstevska ◽  
Tatjana Milenkovic ◽  
Snezana Markovik-Temelkova ◽  
Sasa Jovanovska-Misevska ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Hormone Replacement Therapy ◽  
Glycemic Control ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Control Group ◽  
Natural Menopause ◽  
Glucose Levels

Abstract Introduction. In women with diabetes, the changes that accompany menopause may further diminish glycemic control. Little is known about how hormone replacement therapy (HRT) affects glucose metabolism in diabetes. The aim of this study was to examine whether HbA1C levels are influenced by current HRT among postmenopausal women with type 2 diabetes. Methods. A total of 40 postmenopausal women with type 2 diabetes were enrolled. All of them fulfilled the criteria of natural menopause, with intact uterus, low estrogen levels (E2) and high follicle-stimulating hormone (FSH) levels. Half of them (20 women) were assigned to take HRT (DM-HRT group). The other half (20 women) were assigned to the control group, those who did not take HRT (DM-non HRT group). HRT consisted of 17 β-estradiol (E2) 1 mg and drospirenone (DRSP) 2 mg. Fasting plasma glycemia, insulinemia and HbA1C were followed in both groups throughout 12 months. Results. The mean age was 49 years (SD±3,3) and 48,5 (SD±3.1), respectively. HRT was associated with statistically significant decrease in serum fasting glucose, HbA1C and insulinemia levels in the DM-HRT group. There was no significant reduction in glucose levels and HbA1C together with no significant increase in insulinemia levels in the DM non-HRT group throughout 12 months. Conclusion. HRT was associated with statistically significant decrease of plasma glucose levels and HbA1C level. Larger clinical trials are necessary to understand whether HRT may improve glycemic control in women with diabetes, especially when it is given shortly after entering menopause.

scholarly journals Evaluation of Serum Clusterin Levels in Type 2 Diabetic Men with and without Cardiovascular Disease

2020 ◽  
pp. 978-984
Author(s):  
Safa S. Fayez ◽  
Rashied. M. Rashied ◽  
Shakir F.T. Al-Alaaraji
Keyword(s):  
Insulin Resistance ◽  
Cardiovascular Disease ◽  
Troponin I ◽  
Serum Levels ◽  
The Other ◽  
Control Group ◽  
Model Assessment ◽  
Fasting Serum ◽  
Myocardial Infraction

Objectives: The objective of this study was to evaluate serum levels of clusterin (CLU) in type 2 diabetics with and without cardiovascular disease and to explore possible correlations with insulin resistance and related progression of cardiovascular disease in Iraqi men. Methods: Sixty-three T2DM patients, including forty-two with cardiovascular disease (CVD), were divided into three subgroups; twenty-one with myocardial infraction (MI), twenty-one with other CVD, and twenty-one without any cardiac complication. In addition, a group of twenty-one men served as healthy controls (HCs) for comparison purposes. The four groups were analyzed for parameters that included fasting serum glucose (FSG), lipid profile, fasting serum insulin (FSI), homeostasis model assessment of insulin resistance (HOMA-IR), cardiac Troponin-I (cTn-I),  CK-MB, and some other biochemical variables. Results: Our results showed that the serum CLU levels were higher in T2DM with MI than  the other groups of patients, while the levels were significantly elevated in the entire T2DM group as compared to the control group. Serum levels of CLU showed significantly positive correlations with cTn-I and CK-MB (r= 0.658 p < 0.01and r = 0.575, p < 0.01 , respectively), whereas the correlation with HDL-C was negative. However, the other parameters exhibited weak correlations with serum CLU levels. Conclusions: CLU participates in the event of cardiovascular disease and insulin resistance    in Iraqi males with T2DM and may be used as predictor for CVD development in T2DM patients.

scholarly journals Effects of Hormone Replacement Therapy on Insulin Resistance and Platelet Function Tests

2009 ◽  
Vol 18 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Fulden Sara&ccedil; ◽  
G&uuml;ray Saydam ◽  
Fahri Sahin ◽  
Kemal &Ouml;ztekin ◽  
Fusun Sayg&inodot;l&inodot; ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Platelet Function ◽  
Hormone Replacement ◽  
Platelet Function Tests ◽  
Function Tests

scholarly journals β-Cell function or insulin resistance was associated with the risk of type 2 diabetes among women with or without obesity and a history of gestational diabetes

2020 ◽  
Vol 8 (1) ◽  
pp. e001060
Author(s):  
Yuxin Fan ◽  
Leishen Wang ◽  
Huikun Liu ◽  
Shuang Zhang ◽  
Huiguang Tian ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Diabetes Risk ◽  
Model Assessment ◽  
Β Cell ◽  
Cell Dysfunction ◽  
Homeostatic Model Assessment ◽  
History Of ◽  
Postpartum Diabetes ◽  
Homeostatic Model

IntroductionTo evaluate the single association of postpartum β-cell dysfunction and insulin resistance (IR), as well as different combinations of postpartum β-cell dysfunction, IR, obesity, and a history of gestational diabetes mellitus (GDM) with postpartum type 2 diabetes risk.Research design and methodsThe study included 1263 women with prior GDM and 705 women without GDM. Homeostatic model assessment was used to estimate homeostatic model assessment of β-cell secretory function (HOMA-%β) and homeostatic model assessment of insulin resistance (HOMA-IR).ResultsMultivariable-adjusted ORs of diabetes across quartiles of HOMA-%β and HOMA-IR were 1.00, 1.46, 2.15, and 6.25 (ptrend <0.001), and 1.00, 2.11, 5.59, and 9.36 (ptrend <0.001), respectively. Women with IR only had the same diabetes risk as women with β-cell dysfunction only. Obesity, together with IR or β-cell dysfunction, had a stronger effect on diabetes risk. This stronger effect was also found for a history of GDM with IR or β-cell dysfunction. Women with three risk factors, including obesity, a history of GDM and β-cell dysfunction/IR, showed the highest ORs of diabetes.Conclusionsβ-cell dysfunction or IR was significantly associated with postpartum diabetes. IR and β-cell dysfunction, together with obesity and a history of GDM, had the highest ORs of postpartum diabetes risk.

scholarly journals Increased circulating levels of musclin in newly diagnosed type 2 diabetic patients

2017 ◽  
Vol 14 (2) ◽  
pp. 116-121 ◽  
Author(s):  
Wen-Jia Chen ◽  
Yue Liu ◽  
Yu-Bin Sui ◽  
Bo Zhang ◽  
Xiao-Hui Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Plasma Levels ◽  
Control Group ◽  
Diabetic Patients ◽  
Model Assessment ◽  
Newly Diagnosed

Background: Musclin is a newly identified skeletal muscle–derived secretory factor, which has been recently characterized as a stimulator that induces insulin resistance in mice. However, the pathophysiological role of musclin in humans remains poorly understood. The aim of this study was to explore the potential correlations between musclin plasma levels and various metabolic parameters in patients with type 2 diabetes mellitus. Materials and methods: In this hospital-based study, plasma samples were collected from the enrolled individuals, including 38 newly diagnosed, treatment-naive type 2 diabetes mellitus patients and 41 age- and gender-matched control subjects. Plasma musclin levels were examined by radioimmunoassay. Results: Compared with the control group, musclin plasma levels were significantly higher in untreated type 2 diabetes mellitus patients. Musclin levels in the plasma of newly diagnosed type 2 diabetes mellitus patients were positively correlated with fasting plasma glucose, haemoglobin A1c, serum insulin, triglycerides and homeostasis model assessment of insulin resistance. Furthermore, multivariate logistic regression analysis showed that the level of musclin was associated with the presence of type 2 diabetes mellitus. Receiver operating characteristic curve analysis yielded an area under the curve for musclin of 0.718 in type 2 diabetes mellitus. Conclusion: The circulating concentration of musclin was significantly increased in type 2 diabetes mellitus patients. Our results suggest that musclin has a strong relationship with insulin resistance in type 2 diabetes mellitus.

Sign in / Sign up

Export Citation Format

Share Document